, low-GWP propellants, and its Holmes Chapel site as a specialist pMDI manufacturinghub within the global pharmaceutical supply chain. Positioned in the North West of England’s inhalation R&D and manufacturing cluster, the site contributes high value skills, advanced technical expertise and long-term investment in sustainable inhaler manufacturing, for the benefit of patients and healthcare systems worldwide.

Giuseppe Accogli,Chiesi Group CEO, added:“This agreement strengthens an already established partnership with Bespak, and is aconcrete example of how we translate our ambition into action. By working with trusted partners across our value chain, we can deliver sustainable innovation at scale while ensuring that patients receive their needed therapies.”

Chris Hirst,Bespak CEO, said: “Our collaboration with Chiesi has grown over time around ashared commitment to patient safety, technical excellence and sustainability. By deepening this
=*=*=*=*=*=
当前为第4/9页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页